Other Links


Niftyviews.com is now being managed as an open source website were in anyone can post on the websiteWe advise utmost reader discretion while reading the posts. We cannot guarantee the genuineness of the content on the website.There is no original content posted on the website and all content is sourced from available third party providers

November 11, 2014

Is Venus remedies a sinking ship

Venus remedies came out with an announcement of Swiss approval for the Market Authorization for Meropenem from SWITZERLAND


Post the announcement and the flash in all news hungry stock channels the stock spurted.At the end of the day stock closed up 1% down 4% from its intraday high.

Recently the company has been in news for its rating being downgraded by CRISIL to D 
 technically means a potential default.

Venus had in past defaulted on its FCCB payments and then did Out of court settlements with the FCCB owners

Today when the company posted a rosy picture to all the traders in the market someone was silently selling

 The block deal in nse showed who was selling the stock.It was one of the promoters who sold the stock in open market after sending a positive media announcement.When the promoter wants to jump the ship I rest my case.

 11/11/2014 VENUSREM      Venus Remedies Limited     PAWAN      CHAUDHARY  SELL 72000  263.87   


November 7, 2014

Oops! Did FDA Mistakenly Give Ranbaxy Approval to Sell Generic Nexium? ....What am i reading...

Will an FDA error mean that U.S. consumers will have to wait still longer to buy a generic version of the widely used Nexium heartburn pill?
Ranbaxy, you may recall, was the first generic drug maker to win the right to market a copycat version in the U.S., which would have allowed the company to do so for six months without any competition. The arrangement is designed to reward patent challenges to brand-name drugs and lower health-care costs.
But there has been a snag. The FDA banned imports of Ranbaxy products from four different facilities in India due to a raft of regulatory violations. And until manufacturing begins, the six-month market exclusivity remains in place, which means Ranbaxy rivals cannot make their own generic versions.
Last month, however, Ranbaxy executives confidently stated that they expected to be able to proceed with plans to sell generic versions of Nexium, which is marketed by AstraZeneca, and the Valcyte antiviral sold by Roche. Now, though, the FDA has rescinded the tentative approval, although the marketing applications remains under consideration, according to an agency spokeswoman.
What happened? The spokeswoman was unable to provide an immediate explanation, but the drug maker issued a statement saying the FDA decision was made “in error because of the compliance status of the facilities” mentioned in Ranbaxy marketing applications. Although Ranbaxy maintained there were no “data integrity issues,” the drug maker did not offer any further explanation.
We asked a Ranbaxy spokesman for comment and will update you accordingly. [UPDATE: A spokeswoman for Ranbaxy sent us a note saying the drug maker "is disappointed with this development and is actively evaluating all available options to preserve its rights."]
[ANOTHER UPDATE: An FDA spokeswoman says "the FDA is prohibited by law from disclosing information about an unapproved application. However, she adds that applications for selling Valcyte were approved for Endo Laboratories and Dr. Reddy's Laboratories this week."]
The turnabout means that the FDA is likely to face continued pressure over the ongoing delay in the availability of generic Nexium. The reason is simple: consumers are forced to spend more for the brand-name drug and this has riled some politicians.
Two months ago, for instance, Connecticut Attorney General George Jepsen complained about this in a letter to the agency. He calculated that U.S. consumers spend $16.4 million per day, on average, on Nexium and noted that generics typically sell for 20% or less than a brand-name drug within the first year on the market.
He also pointed out that a consent decree that Ranbaxy signed with the FDA in early 2012 set a period of up to three years – through September 2014 – for the drug maker to correct its manufacturing problems. If requirements are not met, Ranbaxy agreed to relinquish exclusivity no later than Sept. 30. A citizen’s petition filed last May by a law firm – on behalf of an unnamed generic drug maker – made the same points.
Perhaps, the alleged error that Ranbaxy cites is an acknowledgement by the FDA hat the agency is now considering whether to allow other generic drug makers to sell Nexium and Valcyte. We also asked the FDA about this stipulation and the status of the consent decree requirements and will pass along any response.
Last July, by the way, Ranbaxy did receive FDA approval to make and sell a generic version of the Diovan heart drug, which was also caught up in the consent decree. In this instance, the drug is being made by a facility in New Jersey, which is the only Ranbaxy plant that is allowed to make drugs for the U.S. market.

November 5, 2014

India infoline result updates

Greaves Cotton (Q2 FY15) – BUY
CMP Rs140, Target Rs232, Upside 65.7%
- Revenues at Rs4.4bn lower by 1.5% yoy; higher than our estimates, Robust growth in three-wheeler engine sales was offset by weakness seen in other segments
- OPM at 12.7% was higher by 149bps yoy and 166bps qoq, expansion was driven by better product mix and cost cutting initiatives implemented
- PAT was at Rs273mn as compared to a loss of Rs80mn in Q2 FY14 marred by Rs148mn exceptional item related to infrastructure equipment business exit
- Maintain our rating to BUY with a 2-year price target of Rs232
Click here for the detailed report on the same.

Tata Communications (Q2 FY15) – BUY
CMP Rs412, Target Rs475, Upside 16.6%
- Revenues miss estimate but margins ahead of expectation; PAT beat aided by interest income on tax refund
- Strength in data revenues offset voice weakness while data margins reclaim 20% threshold
- Expect data to gain further prominence which would mitigate revenue volatility and provide margin support; raise core business EV/EBIDTA multiple to 6.5x on FY16 EBIDTA and retain BUY with revised 9-12 SOTP target of Rs475
Click here for the detailed report on the same.

KEC International Ltd (Q2 FY15) – BUY
CMP Rs102, Target Rs132, Upside 29.4%
- KEC managed to report 22.2% yoy growth in topline led by strong execution in the T&D space
- The outperformance was restricted by subdued performance in SAE business
- Margins contracted 73bps yoy and 35bps qoq due to operating loss at SAE and higher raw material/sales ratio
- Order inflow at Rs11bn was lower than estimate; the management has indicated that it is L1 in orders worth Rs20bn
- Bottomline impacted by high interest costs (+37.9% qoq) and lower margins
- Net Working capital days continued to increase on a sequential basis due to lower customer advances and increase in inventory levels at SAE
- Management remained confident of delivering margins close to 7% in FY15 and 100bps expansion in FY16
- We have lowered our FY15 and FY16 estimates to account for weak H1 FY15 and on expectations of a slower decline in working capital
- Maintain Buy on the stock with a revised price target of Rs132
Click here for the detailed report on the same.

Follow by Email

Sign by Dealighted - Coupons and Deals

Click here for Disclaimer